CTOs on the Move

AccessOne MedCard

www.accessonemedcard.com

 
AccessOne is a leading provider of flexible, co-branded patient financing solutions. Founded by providers, our solution provides a consumer-focused experience which drives high patient satisfaction for our clients. We have helped over one million consumers afford out-of-pocket medical expenses for health systems nationwide. We offer the most comprehensive platform in the industry with funding models that help more providers and programs that reach more patients. All patients qualify for our program with no credit reporting or negative outcomes.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Rajneesh Kumar
Chief Technology Officer Profile
Steven VanLanen
Infrastructure Director, CISO Profile

Funding

AccessOne MedCard raised $225M on 11/19/2019

Similar Companies

Avita Medical

Avita Medical is a publicly listed regenerative medicine company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY). The company`s lead product, ReCell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA- registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use.

The Ohio Willow Wood Company

The Ohio Willow Wood Company is a Mount Sterling, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Graham Medical Products

Graham Medical Products is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Gallagher Medical Products

Gallagher Medical Products is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astellas Gene Therapies

Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.